StockDuty ← Dashboard Aug 25, 2026 05:56 PM ET
CatalystFDA/Bio

IMMATICS: 'BUY' ON ANZU-CEL 1ST HALF 2027 CATALYST AND POTENTIAL LABEL EXPANSION FOR UVEAL MELANOMA - SEEKINGALPHA

Buy rating driven by 2027 Anzu-Cel catalyst and uveal melanoma label expansion potential.

What changed
Why it matters
Buy rating driven by 2027 Anzu-Cel catalyst and uveal melanoma label expansion potential.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →